These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11410480)

  • 41. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
    Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
    Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma.
    Kanellou P; Zaravinos A; Zioga M; Spandidos DA
    Br J Dermatol; 2009 Jun; 160(6):1215-21. PubMed ID: 19298278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detailed gene expression analysis but not microsatellite marker analysis of 9p21 reveals differential defects in the INK4a gene locus in the majority of head and neck cancers.
    Grüttgen A; Reichenzeller M; Jünger M; Schlien S; Affolter A; Bosch FX
    J Pathol; 2001 Jul; 194(3):311-7. PubMed ID: 11439363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Re: Oda et al. Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. J Pathol 2005;207:410-421.
    Perrone F; Tamborini E; Suardi S; Lagonigro MS; Pilotti S
    J Pathol; 2006 Jun; 209(2):281; author reply 282. PubMed ID: 16622896
    [No Abstract]   [Full Text] [Related]  

  • 46. [Gene therapy for ovarian cancer].
    Hamada K
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():552-61. PubMed ID: 16416852
    [No Abstract]   [Full Text] [Related]  

  • 47. Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma.
    Swellam M; El-Arab LR; Adly A
    Clin Biochem; 2008 Sep; 41(13):1059-66. PubMed ID: 18602381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
    Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
    Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.
    Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y
    Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
    O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
    Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Editorial comment on 'A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy' by Schmitt et al.
    Hayward RL; Smyth JF
    Eur J Cancer; 2002 Nov; 38(17):2207-9. PubMed ID: 12441255
    [No Abstract]   [Full Text] [Related]  

  • 52. p53-based gene therapy of ovarian cancer: magic bullet?
    Berchuck A; Bast RC
    Gynecol Oncol; 1995 Nov; 59(2):169-70. PubMed ID: 7590466
    [No Abstract]   [Full Text] [Related]  

  • 53. [Therapy of ovarian carcinoma].
    Cepický P; Cizková J; Koleilatová A; Kobilková
    Cesk Gynekol; 1981 Feb; 46(1):59-67. PubMed ID: 7273183
    [No Abstract]   [Full Text] [Related]  

  • 54. Therapy of ovarian carcinoma.
    Schwartz SA
    Med Ann Dist Columbia; 1969 Dec; 38(12):669-71. PubMed ID: 5261335
    [No Abstract]   [Full Text] [Related]  

  • 55. The battle between tumor suppressors: is gene therapy using p16(INK4a) more efficacious than p53 for treatment of ovarian carcinoma?
    Murphy ME
    Clin Cancer Res; 2001 Jun; 7(6):1487-9. PubMed ID: 11410480
    [No Abstract]   [Full Text] [Related]  

  • 56. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
    Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
    Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
    Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
    Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
    Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The INK4a/ARF network in tumour suppression.
    Sherr CJ
    Nat Rev Mol Cell Biol; 2001 Oct; 2(10):731-7. PubMed ID: 11584300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncogenes in tumors of gallbladder and biliary tract.
    Enjoji M; Nakamuta M; Nawata H
    Fukuoka Igaku Zasshi; 2004 Feb; 95(2):31-5. PubMed ID: 15101197
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.